SAN FRANCISCO, October 30, 2025 — Leads & Copy — Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) will present a trial-in-progress poster for the Phase 3 OPERA-02 trial at the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), which takes place December 9-12 in San Antonio, TX. The trial is evaluating palazestrant combined with ribociclib in frontline estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.
The poster presentation, titled “OPERA-02: a phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer,” Abstract Number: 264, Presentation Number: PS5-12-18, will be presented on Friday, December 12, 2025 from 12:30pm–2:00pm CT / 1:30pm–3:00pm ET.
Olema Oncology is committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Their lead product candidate, palazestrant (OP-1250), is currently in two Phase 3 clinical trials. Olema is also developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study.
Palazestrant (OP-1250) has been granted FDA Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. It is being evaluated as a single agent in the ongoing pivotal Phase 3 clinical trial, OPERA-01 and in combination with ribociclib in the ongoing pivotal Phase 3 clinical trial, OPERA-02.
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
Source: Olema Pharmaceuticals, Inc.
